Back to companies

Translate Bio Inc: Overview

Want to continue viewing company data?

Sign up for exclusive competitive intelligence.
Company Data Subscription $329 per month (billed Annually)
Signup to View Free Sample

Translate Bio Inc (Translate Bio), formerly RaNA Therapeutics Inc, is a healthcare service provider that develops therapies targeting RNA within cells in the body to selectively activate protein expression. The company provides platform oligonucleotides (oligos) are molecules designed to target specific areas of RNA. Its platform uses two distinct approaches to activate RNA during transcription and post-transcription. Translate Bio provides target treatment areas such as spinal muscular atrophy and friedreich’s ataxia. It offers other target treatment areas such as musculoskeletal disease, inflammatory disease and liver disease. The company provides investment partners such as Atlas Venture, Monsanto, MS Ventures, Omega Funds, Partners Innovation Fund, Pfizer Venture Investments and SR One, among others. Translate Bio is headquartered in Lexington, Massachusetts, the US

Headquarters United States of America

Address 29 Hartwell Ave, Lexington, Massachusetts, 02421-3102


Telephone 1 617 9457361

No of Employees 122

Industry Pharmaceuticals and Healthcare

Revenue (2020) $138.8M

   

   

Explore premium data & analytics

20+

Pipeline Drugs

Identify which of Translate Bio Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

19+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Translate Bio Inc’s relevant decision makers and contact details.

4

Clinical Trials

Determine Translate Bio Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

2

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

2

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

Subscribe to Company Analytics & gain access to premium industry data & analytics Subscribe to Company Analytics & gain access to premium industry data & analytics Start Here

Products and Services

Products
Technology Platform
Oligonucleotide
Subscribe to Company Analytics for access to more products & services data Subscribe to Company Analytics for access to more products & services data Learn More

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2021 Ownership Changes In September, the company was acquired by Sanofi, a pharmaceutical industry company.
2021 Others In June, the company and Sanofi Pasteur initiated a Phase 1 clinical trial evaluating an mRNA-based investigational vaccine against seasonal influenza.
2020 Contracts/Agreements In March, the company and Sanofi's vaccines global business unit, Sanofi Pasteur collaborated with the Translate Bio for the development of a novel messenger RNA (mRNA) vaccine for COVID-19.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Get Started
Image for loader

Competitor Comparison

Key Parameters Translate Bio Inc Cellular Biomedicine Group Inc Gotham Therapeutics Corp Novartis Gene Therapies ReveraGen BioPharma Inc
Headquarters United States of America United States of America United States of America United States of America United States of America
City Lexington Rockville New York City Bannockburn Rockville
State/Province Massachusetts Maryland New York Illinois Maryland
No. of Employees 122 217 - - 11
Entity Type Private Private Private Private Private
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Executives
Name Position Board Since Age
Daniel Lynch Chairman Executive Board 2012 62
Ronald C. Renaud, Jr. Chief Executive Officer; Director Executive Board 2014 52
Brendan Smith Corporate Strategy; Chief Financial Officer Senior Management 2021 -
Paul Burgess Chief Operating Officer; Chief Legal Officer; Secretary Senior Management 2016 47
Frank DeRosa Chief Technology Officer Senior Management - -
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Gain more insight into company management & employee structure with Company Analytics Gain more insight into company management & employee structure with Company Analytics Subscribe

Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer